320 / 1631
Overview of talk
1. Review of clinical data on management of
early stage HL
- Combined modality treatment
- Progress and pitfalls with FDG-PET response
adjusted therapy omitting RT
2. Moving towards personalised approaches to
treatment of early stage HL
- Risk / benefit assessments